Critical COVID-19 represents an endothelial disease with high similarity to kidney disease on the molecular level
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
In patients with critical or mild COVID19 (WHO stages 6-8 [n=53] and stages 1-3 [n=66]), 593 urinary peptides significantly affected by disease severity were identified, reflecting the molecular pathophysiology associated with the course of the infection. The peptide profiles were similar compared with those observed in kidney disease, a prototype of target organ damage with major microvascular involvement, thereby confirming the observation that endothelial damage is a hallmark of COVID19. The clinical corollary is that COVID19 is an indication for anti-oxidative, anti-inflammatory and immunosuppressive treatment modalities protecting the endothelial lining.
Article activity feed
-
SciScore for 10.1101/2021.02.22.21252207: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This study was approved by the local ethics committee (Saxon Chamber of Physicians, registry number #EK-BR-88/20-1), with a waiver of informed consent and by the Institutional Review Boards of all participating centres.
Consent: This study was approved by the local ethics committee (Saxon Chamber of Physicians, registry number #EK-BR-88/20-1), with a waiver of informed consent and by the Institutional Review Boards of all participating centres.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Immunophenotyping of lymphocytes was performed by an … SciScore for 10.1101/2021.02.22.21252207: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This study was approved by the local ethics committee (Saxon Chamber of Physicians, registry number #EK-BR-88/20-1), with a waiver of informed consent and by the Institutional Review Boards of all participating centres.
Consent: This study was approved by the local ethics committee (Saxon Chamber of Physicians, registry number #EK-BR-88/20-1), with a waiver of informed consent and by the Institutional Review Boards of all participating centres.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Immunophenotyping of lymphocytes was performed by an 8-color T (CD3+), and B (CD19+) cytometry with monoclonal antibodies including anti-CD99 (BD Biosciences, supplementary figure 1) on BD FACSLyric™ flow cytometer (BD Biosciences). CD3+suggested: Noneanti-CD99suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-